ALMANAC is the name of a major breast cancer trial. The acronym stands for Axillary Lymphatic Mapping Against Nodal Axillary Clearance. This major randomized trial performed in several centers in the UK produced clear evidence that sentinel node biopsy (SNB), used to stage axillary spread of disease, can be used with low failed localization and false negative rates, provided both radioisotope and blue dye are used to locate the sentinel nodes.
|This oncology article is a stub. You can help WikiMD by expanding it.|